Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2010
Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 47 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase III Randomized, Double-Blind, Placebo-Controlled Evaluation of Citalopram for the Treatment of Hot Flashes
Citalopram Improves Vasomotor and Urogenital Syndromes in Mexican Patients With Post-menopause
Who cites it
47 citing papers in PubMed, 3 syntheses or guidelines pooled it, 129 citations in OpenAlex.
- Does the placebo effect on hot flashes depend on the placebo dose?Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Pooled it
- Variation in menopausal vasomotor symptoms outcomes in clinical trials: a systematic review.BJOG : an international journal of obstetrics and gynaecology · 2020Pooled it
- Informing hot flash treatment decisions for breast cancer survivors: a systematic review of randomized trials comparing active interventions.Breast cancer research and treatment · 2016Pooled it
- Efficacy of a biobehavioral intervention for hot flashes: a randomized controlled pilot study.Menopause (New York, N.Y.) · 2017Trial
- Phase II evaluation of S-adenosyl-L-methionine (SAMe) for the treatment of hot flashes.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016Trial
- κ Agonists as a novel therapy for menopausal hot flashes.Menopause (New York, N.Y.) · 2015Trial
- North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes.Menopause (New York, N.Y.) · 2015Trial
- Effects of low-dose paroxetine 7.5 mg on weight and sexual function during treatment of vasomotor symptoms associated with menopause.Menopause (New York, N.Y.) · 2014Trial
- Sexual function in women on estradiol or venlafaxine for hot flushes: a randomized controlled trial.Obstetrics and gynecology · 2014Trial
- Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial.Menopause (New York, N.Y.) · 2012Trial
- Effect of escitalopram on hot flash interference: a randomized, controlled trial.Fertility and sterility · 2012Trial
- Sexual function in nondepressed women using escitalopram for vasomotor symptoms: a randomized controlled trial.Obstetrics and gynecology · 2012Trial
- A phase III, randomized, placebo-controlled, double-blind trial of flaxseed for the treatment of hot flashes: North Central Cancer Treatment Group N08C7.Menopause (New York, N.Y.) · 2012Trial
- Escitalopram treatment of menopausal hot flashes.Menopause (New York, N.Y.) · 2011Trial
- Mindfulness training for coping with hot flashes: results of a randomized trial.Menopause (New York, N.Y.) · 2011Trial
- Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2010Trial
- Neurokinin receptor antagonists for vasomotor symptoms: from KNDy neurons to clinical translation.Nature reviews. Endocrinology · 2026Review
- The impact of coadministration of venlafaxine, citalopram or gabapentin on the metabolic activation of tamoxifen.Breast cancer research and treatment · 2025Article
- Reproductive aging in biological females: mechanisms and immediate consequences.Frontiers in endocrinology · 2025Review
- Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
purposeUp to 75% of women experience hot flashes, which can negatively impact quality of life. As hot flash physiology is not definitively understood, it cannot be assumed that effective agents represent class effects. Therefore, there is a continued need for rigorous evaluation to identify effective nonhormonal options for hot flash relief.
methodsA randomized, double-blind trial evaluated citalopram at target doses of 10, 20, or 30 mg/d versus placebo for 6 weeks. Postmenopausal women with at least 14 bothersome hot flashes per week recorded hot flashes for 7 days before starting treatment and were then titrated to their target doses. The primary end point was the change from baseline to 6 weeks in hot flash score.
resultsTwo hundred fifty-four women were randomly assigned onto this study. Data for hot flash scores and frequencies showed significant improvement in hot flashes with citalopram over placebo, with no significant differences among doses. Reductions in mean hot flash scores were 2.0 (23%), 7.0 (49%), 7.7 (50%), and 10.7 (55%) for placebo and 10, 20, and 30 mg of citalopram, respectively (P <or= .002). Improvement in secondary outcomes, such as the Hot Flash Related Daily Interference Scale, was statistically superior in the 20-mg arm. Citalopram was well-tolerated, with no significant negative adverse effects.
conclusionCitalopram is an effective, well-tolerated agent in managing hot flashes. There does not appear to be a significant dose response above 10 mg/d, but broader helpful effects of the agent appear to be more evident at 20 mg/d.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.